Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.

December 2022

SFA Therapeutics will begin testing of SFA001 in a Phase 1 exploratory trial at Einstein Hospital in Philadelphia 1Q 2023 Dr Manisha Verma MD, MPH to act as principal investigator SFA Therapeutics to test its novel anti-inflamaatory compound, SFA001 in NASH patients. SFA001 is a powerful microbiome derived orally active small molecule has been shown to greatly reduce chronic inflammation. Chronic inflammation leads to the activation of...

Read More

Tales From the 2022 Biotech VC Fundraising Trail After the bonanza of 2021, life-sciences entrepreneurs reset their expectations as financing contracted SFA Therapeutics CEO & Co-Founder, Ira Spector, PhD discusses Startup Biotech funding in The Wall Street Journal Wall Street Journal article titled   'Biotech Startup Fundraising Fell in 2022.'by Brian Gormley in the December 23, 2022, print edition. ...

Read More